These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 17527093

  • 21. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P, Tsiodras S, Antoniadou A, Katsarolis I, Papadopoulos A, Poulakou G, Giamarellou H.
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [Abstract] [Full Text] [Related]

  • 22. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
    Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, Juárez-Kasusky I, Magana-Aquino M, Ramos-Santos C, Pérez-Saleme L, Rangel-Frausto S, Antuna-Puente B, Soto-Ramírez LE, Lima V, Belaunzarán-Zamudio F, Crabtree-Ramírez B, Montaner J.
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
    [Abstract] [Full Text] [Related]

  • 23. [The "induction-maintenance" strategy].
    Arribas López JR.
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():8-11. PubMed ID: 19572438
    [Abstract] [Full Text] [Related]

  • 24. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM, Advanz-3 Study Group.
    J Acquir Immune Defic Syndr; 2015 Jun 01; 69(2):206-15. PubMed ID: 25831464
    [Abstract] [Full Text] [Related]

  • 25. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P, SWITCHMRK 1 and 2 investigators.
    Lancet; 2010 Jan 30; 375(9712):396-407. PubMed ID: 20074791
    [Abstract] [Full Text] [Related]

  • 26. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 Jan 30; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 27. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 Jan 30; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 28. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR, Conroy AL, Gamble JL, Papp E, Hawkes M, Olwoch P, Natureeba P, Kamya M, Silverman M, Cohan D, Koss CA, Dorsey G, Kain KC, Serghides L.
    Clin Infect Dis; 2018 Jan 18; 66(3):428-436. PubMed ID: 29136115
    [Abstract] [Full Text] [Related]

  • 29. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
    Negredo E, Moltó J, Burger D, Côté H, Miró O, Ribalta J, Martínez E, Puig J, Ruiz L, Salazar J, López S, Montaner J, Rey-Joly C, Clotet B.
    J Acquir Immune Defic Syndr; 2005 Jan 01; 38(1):47-52. PubMed ID: 15608524
    [Abstract] [Full Text] [Related]

  • 30. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
    Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ.
    AIDS Res Hum Retroviruses; 2007 Dec 01; 23(12):1505-14. PubMed ID: 18160008
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P.
    Antivir Ther; 2007 Dec 01; 12(8):1265-71. PubMed ID: 18240866
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L, Liu A, Zhang H, Wu H, Zhang T, Su B, Shao Y, Li J, Ye J, Scott SR, Mahajan SD, Schwartz SA, Yu H, Sun L.
    Curr HIV Res; 2019 Dec 01; 17(5):324-334. PubMed ID: 31654514
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.
    AIDS; 2009 Sep 10; 23(14):1829-40. PubMed ID: 19474650
    [Abstract] [Full Text] [Related]

  • 38. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
    Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D.
    J Acquir Immune Defic Syndr; 2014 Oct 01; 67(2):128-35. PubMed ID: 25072616
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.